Our data that reduced Apaf-1 expression did not correlate with 5-year survival of patients with primary melanoma is consistent with the findings by Fujimoto et al (2004), who showed that Apaf-1 LOH correlated with poorer prognosis of metastatic, but not primary melanoma patients. This evidence concerns the gene APAF1 and melanoma.